Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic Arthritis
Tiago Torres, L. Puig
American Journal of Clinical Dermatology (2017) Vol. 19, Iss. 1, pp. 23-32
Closed Access | Times Cited: 81

Showing 1-25 of 81 citing articles:

Psoriasis and Treatment: Past, Present and Future Aspects
Claire Reid, C.E.M. Griffiths
Acta Dermato Venereologica (2020) Vol. 100, Iss. 3, pp. 70-80
Open Access | Times Cited: 164
Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials
Mark Lebwohl, Richard B. Warren, Howard Sofen, et al.
British Journal of Dermatology (2024) Vol. 190, Iss. 5, pp. 668-679
Open Access | Times Cited: 28
Nail psoriasis: clinical features, pathogenesis, differential diagnoses, and management
Eckart Haneke
Psoriasis Targets and Therapy (2017) Vol. Volume 7, pp. 51-63
Open Access | Times Cited: 101
New and Emerging Oral/Topical Small-Molecule Treatments for Psoriasis
Elena Carmona‐Rocha, Lluís Rusiñol, L. Puig
Pharmaceutics (2024) Vol. 16, Iss. 2, pp. 239-239
Open Access | Times Cited: 16
Exploring the Therapeutic Landscape: A Narrative Review on Topical and Oral Phosphodiesterase-4 Inhibitors in Dermatology
Elena Carmona‐Rocha, Lluís Rusiñol, L. Puig
Pharmaceutics (2025) Vol. 17, Iss. 1, pp. 91-91
Open Access | Times Cited: 1
Safety assessment of apremilast: real-world adverse event analysis from the FAERS database
Landong Ren, Kaidi Zhao, Bingqing Wang, et al.
Archives of Dermatological Research (2025) Vol. 317, Iss. 1
Closed Access | Times Cited: 1
Commentary: Phosphodiesterase 4 inhibitors as potential adjunct treatment targeting the cytokine storm in COVID-19
Μaria Dalamaga, Ιrene Karampela, Christos S. Mantzoros
Metabolism (2020) Vol. 109, pp. 154282-154282
Open Access | Times Cited: 57
Retinoic acid-related orphan receptor gamma t (RORγt) inverse agonists/antagonists for the treatment of inflammatory diseases – where are we presently?
Christian Gege
Expert Opinion on Drug Discovery (2021) Vol. 16, Iss. 12, pp. 1517-1535
Closed Access | Times Cited: 44
Deciphering Gut Microbiota Dysbiosis and Corresponding Genetic and Metabolic Dysregulation in Psoriasis Patients Using Metagenomics Sequencing
Shiju Xiao, Guangzhong Zhang, Chunyan Jiang, et al.
Frontiers in Cellular and Infection Microbiology (2021) Vol. 11
Open Access | Times Cited: 42
Novel Therapeutic Approaches to Psoriasis and Risk of Infectious Disease
Alfonso Motolese, Manuela Ceccarelli, Laura Macca, et al.
Biomedicines (2022) Vol. 10, Iss. 2, pp. 228-228
Open Access | Times Cited: 29
Novel Therapies in Plaque Psoriasis: A Review of Tyrosine Kinase 2 Inhibitors
George Martin
Dermatology and Therapy (2023) Vol. 13, Iss. 2, pp. 417-435
Open Access | Times Cited: 21
Apremilast prevents blistering in human epidermis and stabilizes keratinocyte adhesion in pemphigus
Anna M. Sigmund, Markus Winkler, Sophia Engelmayer, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 20
<p>Diagnosis, Screening and Treatment of Patients with Palmoplantar Pustulosis (PPP): A Review of Current Practices and Recommendations</p>
Egídio Freitas, Maria Alexandra Rodrigues, Tiago Torres
Clinical Cosmetic and Investigational Dermatology (2020) Vol. Volume 13, pp. 561-578
Open Access | Times Cited: 45
Real life experience of apremilast in psoriasis and arthritis psoriatic patients: Preliminary results on metabolic biomarkers
Sara Mazzilli, Caterina Lanna, Carlo Chiaramonte, et al.
The Journal of Dermatology (2020) Vol. 47, Iss. 6, pp. 578-582
Closed Access | Times Cited: 42
New Topical Therapies for Psoriasis
Ana Maria Lé, Tiago Torres
American Journal of Clinical Dermatology (2021) Vol. 23, Iss. 1, pp. 13-24
Closed Access | Times Cited: 37
The roles of T cells in psoriasis
Peng Zhang, Yuwen Su, Siying Li, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 16
New and Emerging Biological and Oral/Topical Small-Molecule Treatments for Psoriasis
Elena Carmona‐Rocha, Lluís Rusiñol, L. Puig
(2024)
Open Access | Times Cited: 6
Adenosine and Its Receptors in the Pathogenesis and Treatment of Inflammatory Skin Diseases
Luxia Chen, Lei Xuan, Karsten Mahnke
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 11, pp. 5810-5810
Open Access | Times Cited: 5
Investigational drugs in clinical trials for Hidradenitis Suppurativa
Peter Theut Riis, Linnea Thorlacius, Gregor B. E. Jemec
Expert Opinion on Investigational Drugs (2017) Vol. 27, Iss. 1, pp. 43-53
Closed Access | Times Cited: 45
Contractility of the epididymal duct - function, regulation and potential drug effects
Vera Elfgen, Andrea Mietens, Marco Mewe, et al.
Reproduction (2018)
Open Access | Times Cited: 45
Psoriasis in HIV infection: an update
Miguel Alpalhão, João Borges‐Costa, Paulo Filipe
International Journal of STD & AIDS (2019) Vol. 30, Iss. 6, pp. 596-604
Closed Access | Times Cited: 39
Managing Psoriasis in Patients with HBV or HCV Infection: Practical Considerations
Stefano Piaserico, Francesco Messina, Francesco Paolo Russo
American Journal of Clinical Dermatology (2019) Vol. 20, Iss. 6, pp. 829-845
Closed Access | Times Cited: 38
PDE4 Inhibitors: Profiling Hits through the Multitude of Structural Classes
Jin Jian, Francesca Mazzacuva, Letizia Crocetti, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 14, pp. 11518-11518
Open Access | Times Cited: 12
Treatment of psoriasis with biologic and non‐biologic targeted therapies in patients with latent tuberculosis infection or at risk for tuberculosis disease progression: Recommendations from a SPIN‐FRT expert consensus
Tiago Torres, Nicolò Costantino Brembilla, Richard Langley, et al.
Journal of the European Academy of Dermatology and Venereology (2024)
Closed Access | Times Cited: 4
Current and Future Therapies for Psoriasis with a Focus on Serotonergic Drugs
A.M. Martins, Andreia Ascenso, Helena Margarida Ribeiro, et al.
Molecular Neurobiology (2020) Vol. 57, Iss. 5, pp. 2391-2419
Closed Access | Times Cited: 28
Page 1 - Next Page

Scroll to top